Literature DB >> 30696519

Ketamine Tolerance in Sprague-Dawley Rats after Chronic Administration of Ketamine, Morphine, or Cocaine.

Samantha A Gerb1, Jemma E Cook2, Alexandria E Gochenauer, Camille S Young3, Lindak K Fulton3, Andrew W Grady3, Kevin B Freeman2.   

Abstract

Ketamine is one of the most commonly used anesthetics in human and veterinary medicine, but its clinical effectiveness is often compromised due to tolerance to its anesthetic effects. Although ketamine tolerance has been demonstrated in a number of behavioral measures, no published work has investigated tolerance to ketamine's anesthetic effects other than duration of anesthesia. In addition, a reported practice in anesthesiology is to alter anesthetic doses for procedures when the patient has a history of drug abuse. Empirically investigating the effects of administration of a drug of abuse on ketamine's potency and efficacy to produce anesthesia could help in the creation of anesthetic plans that maximize safety for both clinicians and patients. The goal of the current study was to test the effects of repeated administration of ketamine, morphine, or cocaine on ketamine's ability to produce anesthesia. In 2 studies, male Sprague-Dawley rats received daily injections of ketamine (32 or 100 mg/kg IP), morphine (3.2 or 5.6 mg/kg IP), or cocaine (3.2 or 10 mg/kg IP) for 14 consecutive days and then were tested on day 15 for ketamine-induced anesthesia by using a cumulative-dosing procedure (32 to 320 mg/kg IP). Chronic treatment with either ketamine or morphine-but not cocaine-produced tolerance to ketamine's anesthetic effects in a dose-dependent manner. These results suggest that ketamine's clinical effectiveness as an anesthetic will vary as a function of its history of use. Furthermore, given that chronic morphine administration produced tolerance to ketamine's anesthetic effects, various pain medications may reduce ketamine's effectiveness for anesthesia.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30696519      PMCID: PMC6382050          DOI: 10.30802/AALAS-CM-18-000053

Source DB:  PubMed          Journal:  Comp Med        ISSN: 1532-0820            Impact factor:   0.982


  37 in total

1.  The development of an acute tolerance to ketamine.

Authors:  J F Cumming
Journal:  Anesth Analg       Date:  1976 Nov-Dec       Impact factor: 5.108

2.  Repeated ketamine administration redeems the time lag for citalopram's antidepressant-like effects.

Authors:  G-F Zhang; W-X Liu; L-L Qiu; J Guo; X-M Wang; H-L Sun; J-J Yang; Z-Q Zhou
Journal:  Eur Psychiatry       Date:  2015-03-18       Impact factor: 5.361

3.  Ketamine changes the local resting-state functional properties of anesthetized-monkey brain.

Authors:  Jia-Sheng Rao; Zuxiang Liu; Can Zhao; Rui-Han Wei; Wen Zhao; Peng-Yu Tian; Xia Zhou; Zhao-Yang Yang; Xiao-Guang Li
Journal:  Magn Reson Imaging       Date:  2017-07-26       Impact factor: 2.546

4.  Development of tolerance to ketamine in an infant undergoing repeated anesthesia.

Authors:  D E Byer; A B Gould
Journal:  Anesthesiology       Date:  1981-03       Impact factor: 7.892

5.  Rapid development of tolerance to sub-anaesthetic dose of ketamine: an oculomotor study in macaque monkeys.

Authors:  Pierre Pouget; Nicolas Wattiez; Sophie Rivaud-Péchoux; Bertrand Gaymard
Journal:  Psychopharmacology (Berl)       Date:  2010-03-23       Impact factor: 4.530

6.  The development of tolerance to ketamine in rats and the significance of hepatic metabolism.

Authors:  A Livingston; A E Waterman
Journal:  Br J Pharmacol       Date:  1978-09       Impact factor: 8.739

7.  Impact of oral ketamine augmentation on hospital admissions in treatment-resistant depression and PTSD: a retrospective study.

Authors:  John Hartberg; Simone Garrett-Walcott; Angelo De Gioannis
Journal:  Psychopharmacology (Berl)       Date:  2017-11-18       Impact factor: 4.530

Review 8.  Illicit drugs and surgery.

Authors:  Andrew P Hall; John A Henry
Journal:  Int J Surg       Date:  2006-08-14       Impact factor: 6.071

9.  Intraperitoneal anaesthesia with propofol, medetomidine and fentanyl in mice.

Authors:  H C Alves; A M Valentim; I A S Olsson; L M Antunes
Journal:  Lab Anim       Date:  2008-11-10       Impact factor: 2.471

10.  Influence of repeated anaesthesia on physiological parameters in male Wistar rats: a telemetric study about isoflurane, ketamine-xylazine and a combination of medetomidine, midazolam and fentanyl.

Authors:  Maike Albrecht; Julia Henke; Sabine Tacke; Michael Markert; Brian Guth
Journal:  BMC Vet Res       Date:  2014-12-31       Impact factor: 2.741

View more
  5 in total

1.  Rapid Recovery and Short Duration Anesthesia after Low Dose Ketamine and High Dose Dexmedetomidine in Rhesus Macaques (Macaca mulatta).

Authors:  Kristin E Killoran; Courtney A Walsh; Jennifer L Asher; Molly B Tarleton; Steven R Wilson
Journal:  J Am Assoc Lab Anim Sci       Date:  2021-03-17       Impact factor: 1.232

2.  Ketamine use disorder: preclinical, clinical, and neuroimaging evidence to support proposed mechanisms of actions.

Authors:  Leah Vines; Diana Sotelo; Allison Johnson; Evan Dennis; Peter Manza; Nora D Volkow; Gene-Jack Wang
Journal:  Intell Med       Date:  2022-03-07

3.  Downregulation of the NLRP3/Caspse-1 Pathway Ameliorates Ketamine-Induced Liver Injury and Inflammation in Developing Rats.

Authors:  Xinzhang Chen; Zhiheng Zhang; Meilun Shen; Xiangying Ma; Di Qiu; Siyao Li; Li Gao
Journal:  Molecules       Date:  2022-05-04       Impact factor: 4.927

4.  Effects of subanesthetic ketamine and (2R,6R) hydroxynorketamine on working memory and synaptic transmission in the nucleus reuniens in mice.

Authors:  Priyodarshan Goswamee; Remington Rice; Elizabeth Leggett; Fan Zhang; Sofia Manicka; Joseph H Porter; A Rory McQuiston
Journal:  Neuropharmacology       Date:  2022-01-20       Impact factor: 5.250

5.  The Effects of Ketamine on the Gut Microbiome on CD1 Mice.

Authors:  Samantha A Gerb; Ryan J Dashek; Aaron C Ericsson; Rachel Griffin; Craig L Franklin
Journal:  Comp Med       Date:  2021-07-23       Impact factor: 0.982

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.